Residual CVD Risk with Intensive Statin Therapy Less, but Still Unacceptably High 40 Statistically significant, but clinically inadequate CVD reduction1 Patients Experiencing Major CVD Events, % 30 26.3 22.4 20 13.7 Standard statin therapy Intensive high-dose statin therapy 12.0 10.9 10 8.7 0 n LDL-C* mg/dL 1Superko 2Cannon PROVE IT-TIMI 222 4162 95 62 104 IDEAL3 8888 81 TNT4 10,001 101 77 HR. Br J Cardiol. 2006;13:131-136. CP et al. N Engl J Med. 2004;350:1495-1504. 3Pedersen TR et al. JAMA. 2005;294:2437-2445. 4LaRosa JC et al. N Engl J Med. 2005;352:1425-1435. *Mean or median LDL-C after treatment